FIREFLY NEUROSCIENCE, INC.
No enriched coverage for $AIFF in the last 7 days.
No SEC Form 4 filings for $AIFF in the last 30 days.
See all $AIFF insider activity →Firefly Neuroscience (AIFF) and NeuroSigma partnered to promote NeuroSigma's Monarch eTNS System, a non-drug ADHD treatment, through Firefly's Evoke platform network. AIFF shares rose 38.9% to $1.65. According to a 2024 study, 7.1 million U.S. children have ADHD, with many seeking non-medication treatments.
Aethlon Medical (AEMD) surged 360% after announcing a merger with North Immunology and a $180M private placement. Tiziana Life Sciences (TLSA) rose 22% due to a clinical trial collaboration. Capricor Therapeutics (CAPR) gained 9% with upcoming Duchenne data. Firefly Neuroscience (AIFF) climbed 26% after a brain-medicine partnership. Clearmind Medicine (CMND) increased 6% following an FDA psychedelic hearing.
Firefly Neuroscience (AIFF) partners with Radial to integrate its Evoke EEG platform with RadialOS, aiming to enhance brain-function diagnostics and treatment personalization. Evoke uses AI to analyze brain activity, aiding in conditions like depression and ADHD. Radial operates 27 clinics, treating thousands annually. AIFF stock is up 11.83% at $1.04.
Recent AIFF coverage spans corporate actions, market movers and technology.
The partnership expands Firefly's reach into pediatric ADHD treatment, likely boosting revenue prospects.
Integration expands clinical utility and market reach of Firefly's brain‑function technology.
The integration could expand Firefly's market reach and enhance Radial's clinical workflow, potentially supporting revenue growth.
Executive turnover may affect short‑term investor sentiment and stock volatility.
The filing signals governance and equity-structure changes that can affect dilution expectations and future option grants.
AlphAI scores every news story that mentions AIFF with an AI model for sentiment and relevance, and aggregates insider trades from FIREFLY NEUROSCIENCE, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Firefly Neuroscience (AIFF) and NeuroSigma partnered to promote NeuroSigma's Monarch eTNS System, a non-drug ADHD treatment, through Firefly's Evoke platform network. AIFF shares rose 38.9% to $1.65. According to a 2024 study, 7.1 million U.S. children have ADHD, with many seeking non-medication treatments.
2 min readAethlon Medical (AEMD) surged 360% after announcing a merger with North Immunology and a $180M private placement. Tiziana Life Sciences (TLSA) rose 22% due to a clinical trial collaboration. Capricor Therapeutics (CAPR) gained 9% with upcoming Duchenne data. Firefly Neuroscience (AIFF) climbed 26% after a brain-medicine partnership. Clearmind Medicine (CMND) increased 6% following an FDA psychedelic hearing.
3 min readFirefly Neuroscience (AIFF) partners with Radial to integrate its Evoke EEG platform with RadialOS, aiming to enhance brain-function diagnostics and treatment personalization. Evoke uses AI to analyze brain activity, aiding in conditions like depression and ADHD. Radial operates 27 clinics, treating thousands annually. AIFF stock is up 11.83% at $1.04.
2 min readFIREFLY NEUROSCIENCE, INC. (AIFF) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 8, 2026, the board of directors (the “Board”) of Firefly Neuroscience, Inc., a Delaware corporation (the “Comp
1 min readFIREFLY NEUROSCIENCE, INC. (AIFF) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 5, 2026, at the 2026 annual meeting of stockholders (the “ Annual Meeting ”) of Firefly Neuroscience, Inc., a Del
4 min readFirefly Neuroscience (NASDAQ: AIFF) said TMS center customer clinical assessments using its FDA 510(k)-cleared AI-powered EEG/ERP platform Evoke rose about 291% year over year, nearly four-fold. The company said Evoke combines qEEG and ERP to support clinician assessment of conditions including depression, anxiety, and ADHD, including monitoring before, during, and after TMS.
3 min readFIREFLY NEUROSCIENCE, INC. (AIFF) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. false 0000803578 0000803578 2026-06-25 2026-06-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Repor
2 min readFIREFLY NEUROSCIENCE, INC. (AIFF) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ea029547601ex10-1.htm EMPLOYMENT AGREEMENT BETWEEN DEEL INNOVATION LTD. AND GIL ISSACHAR, DATED JUNE 18, 2026 Exhibit 10.1 Employment Agreement This Employment Agreement, is entered into on June 18th, 2026 by and between DEEL INNOVATION LTD. , an Israeli company registe
2 min readKENMORE, N.Y. and MIAMI, Sept. 05, 2025 ( GLOBE NEWSWIRE ) -- Firefly Neuroscience, Inc. ( "Firefly" ) ( NASDAQ: AIFF ) , an Artificial Intelligence ( "AI" ) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today ...
2 min readKENMORE, N.Y. and MIAMI, Sept. 05, 2025 ( GLOBE NEWSWIRE ) -- Firefly Neuroscience, Inc. ( "Firefly" ) AIFF, an Artificial Intelligence ( "AI" ) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced a new ...
2 min read
